216 related articles for article (PubMed ID: 35822254)
1. Dynamic
Chen ZY; Fu R; Tan XY; Yan LX; Tang WF; Qiu ZB; Qi YF; Li YF; Hou QY; Wu YL; Zhong WZ; Jiang BY
Thorac Cancer; 2022 Sep; 13(17):2524-2531. PubMed ID: 35822254
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive
Cui Y; Lin Y; Zhao Z; Long H; Zheng L; Lin X
Front Immunol; 2022; 13():994917. PubMed ID: 36466929
[TBL] [Abstract][Full Text] [Related]
3. Utility of
Zhuang F; Haoran E; Huang J; Wu J; Xu L; Zhang L; Li Q; Li C; Zhao Y; Yang M; Ma M; She Y; Chen H; Luo Q; Zhao D; Chen C
Lung Cancer; 2023 Apr; 178():20-27. PubMed ID: 36764154
[TBL] [Abstract][Full Text] [Related]
4. The predictive value of
Yin X; Li J; Chen B; Liu K; Hu S
Lung Cancer; 2023 Dec; 186():107389. PubMed ID: 37820538
[TBL] [Abstract][Full Text] [Related]
5. The efficiency of
Tao X; Li N; Wu N; He J; Ying J; Gao S; Wang S; Wang J; Wang Z; Ling Y; Tang W; Zhang Z
Eur J Nucl Med Mol Imaging; 2020 May; 47(5):1209-1219. PubMed ID: 32043180
[TBL] [Abstract][Full Text] [Related]
6. Use of Fluoro-[18F]-Deoxy-2-D-Glucose Positron Emission Tomography/Computed Tomography to Predict Immunotherapy Treatment Response in Patients With Squamous Cell Oral Cavity Cancers.
Shah H; Wang Y; Cheng SC; Gunasti L; Chen YH; Lako A; Guenette J; Rodig S; Jo VY; Uppaluri R; Haddad R; Schoenfeld JD; Jacene HA
JAMA Otolaryngol Head Neck Surg; 2022 Mar; 148(3):268-276. PubMed ID: 35050348
[TBL] [Abstract][Full Text] [Related]
7. [
Vos JL; Zuur CL; Smit LA; de Boer JP; Al-Mamgani A; van den Brekel MWM; Haanen JBAG; Vogel WV
Eur J Nucl Med Mol Imaging; 2022 May; 49(6):2010-2022. PubMed ID: 34957526
[TBL] [Abstract][Full Text] [Related]
8. Utility of
Chen X; Bai G; Zang R; Song P; Bie F; Huai Q; Li Y; Liu Y; Zhou B; Bie Y; Yang Z; Gao S
Transl Oncol; 2023 Sep; 35():101725. PubMed ID: 37421908
[TBL] [Abstract][Full Text] [Related]
9. Efficacy evaluation of neoadjuvant immunotherapy plus chemotherapy for non-small-cell lung cancer: comparison of PET/CT with postoperative pathology.
Cheng Y; Chen ZY; Huang JJ; Shao D
Eur Radiol; 2023 Oct; 33(10):6625-6635. PubMed ID: 37515634
[TBL] [Abstract][Full Text] [Related]
10. 18F-FDG PET/CT of Non-Small Cell Lung Carcinoma Under Neoadjuvant Chemotherapy: Background-Based Adaptive-Volume Metrics Outperform TLG and MTV in Predicting Histopathologic Response.
Burger IA; Casanova R; Steiger S; Husmann L; Stolzmann P; Huellner MW; Curioni A; Hillinger S; Schmidtlein CR; Soltermann A
J Nucl Med; 2016 Jun; 57(6):849-54. PubMed ID: 26823566
[TBL] [Abstract][Full Text] [Related]
11. FDG PET using SUV
Huang YC; Lu HI; Huang SC; Hsu CC; Chiu NT; Wang YM; Chiu YC; Li SH
BMC Med Imaging; 2017 Jan; 17(1):1. PubMed ID: 28056868
[TBL] [Abstract][Full Text] [Related]
12. The role of
Wang X; Yang W; Zhou Q; Luo H; Chen W; Yeung SJ; Zhang S; Gan Y; Zeng B; Liu Z; Feng S; Zhang X; Cheng C
Eur J Nucl Med Mol Imaging; 2022 Oct; 49(12):4241-4251. PubMed ID: 35732974
[TBL] [Abstract][Full Text] [Related]
13. Areas of high 18F-FDG uptake on preradiotherapy PET/CT identify preferential sites of local relapse after chemoradiotherapy for non-small cell lung cancer.
Calais J; Thureau S; Dubray B; Modzelewski R; Thiberville L; Gardin I; Vera P
J Nucl Med; 2015 Feb; 56(2):196-203. PubMed ID: 25572091
[TBL] [Abstract][Full Text] [Related]
14. Primary tumor standardized uptake value (SUVmax) measured on
Hui Z; Wei F; Ren H; Xu W; Ren X
J Cancer Res Clin Oncol; 2020 Oct; 146(10):2595-2605. PubMed ID: 32494919
[TBL] [Abstract][Full Text] [Related]
15. Combination of Fluorine-18 Fluorodeoxyglucose Positron-Emission Tomography/Computed Tomography (¹⁸F-FDG PET/CT) and Tumor Markers to Diagnose Lymph Node Metastasis in Non-Small Cell Lung Cancer (NSCLC): A Retrospective and Prospective Study.
Zhai X; Guo Y; Qian X
Med Sci Monit; 2020 Jun; 26():e922675. PubMed ID: 32483109
[TBL] [Abstract][Full Text] [Related]
16. Incidence and Clinical Impact of Inflammatory Fluorodeoxyglucose Positron Emission Tomography Uptake After Neoadjuvant Pembrolizumab in Patients with Organ-confined Bladder Cancer Undergoing Radical Cystectomy.
Marandino L; Capozza A; Bandini M; Raggi D; Farè E; Pederzoli F; Gallina A; Capitanio U; Bianchi M; Gandaglia G; Fossati N; Colecchia M; Giannatempo P; Serafini G; Padovano B; Salonia A; Briganti A; Montorsi F; Alessi A; Necchi A
Eur Urol Focus; 2021 Sep; 7(5):1092-1099. PubMed ID: 33172772
[TBL] [Abstract][Full Text] [Related]
17. Metabolic characteristics of programmed cell death-ligand 1-expressing lung cancer on
Takada K; Toyokawa G; Okamoto T; Baba S; Kozuma Y; Matsubara T; Haratake N; Akamine T; Takamori S; Katsura M; Shoji F; Honda H; Oda Y; Maehara Y
Cancer Med; 2017 Nov; 6(11):2552-2561. PubMed ID: 28980429
[TBL] [Abstract][Full Text] [Related]
18. Comments on "dynamic
Wang SY; Shiau YC; Hsu CX
Thorac Cancer; 2022 Dec; 13(24):3513-3514. PubMed ID: 36288468
[No Abstract] [Full Text] [Related]
19.
Takada K; Toyokawa G; Yoneshima Y; Tanaka K; Okamoto I; Shimokawa M; Wakasu S; Haro A; Osoegawa A; Tagawa T; Oda Y; Nakanishi Y; Mori M
Sci Rep; 2019 Sep; 9(1):13362. PubMed ID: 31527660
[TBL] [Abstract][Full Text] [Related]
20. Patlak-Ki derived from ultra-high sensitivity dynamic total body [
Wang D; Qiu B; Liu Q; Xia L; Liu S; Zheng C; Liu H; Mo Y; Zhang X; Hu Y; Zheng S; Zhou Y; Fu J; Chen N; Liu F; Zhou R; Guo J; Fan W; Liu H
Eur J Nucl Med Mol Imaging; 2023 Sep; 50(11):3400-3413. PubMed ID: 37310427
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
